https://médecine.top/index.php?action=history&feed=atom&title=Infection_%C3%A0_HIV 2026-09-02T13:58:35Z Historique des révisions pour cette page sur le wiki MediaWiki 1.35.2 https://médecine.top/index.php?title=Infection_%C3%A0_HIV&diff=2710&oldid=prev 2020-06-18T14:54:14Z

<p></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="fr"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 18 juin 2020 à 14:54</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l1" >Ligne 1 :</td> <td colspan="2" class="diff-lineno">Ligne 1 :</td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== Femme enceinte ==</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* tenofovir disoproxil fumarate (TDF), emtricitabine, and efavirenz.</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Prophylaxie post-expositionnelle (PEP) ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Prophylaxie post-expositionnelle (PEP) ==</div></td></tr> </table>

Julien https://médecine.top/index.php?title=Infection_%C3%A0_HIV&diff=2709&oldid=prev 2020-06-18T14:47:03Z

<p><span dir="auto"><span class="autocomment">Prophylaxie post-expositionnelle (PEP)</span></span></p> <table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="fr"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Version précédente</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Version du 18 juin 2020 à 14:47</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l2" >Ligne 2 :</td> <td colspan="2" class="diff-lineno">Ligne 2 :</td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Prophylaxie post-expositionnelle (PEP) ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Prophylaxie post-expositionnelle (PEP) ==</div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Preferred HIV postexposure prophylaxis regimens include tenofovir disoproxil fumarate, emtricitabine, and either dolutegravir or raltegravir and are appropriate whether the exposure was occupational or nonoccupational.</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Preferred HIV postexposure prophylaxis regimens include tenofovir disoproxil fumarate, emtricitabine, and either dolutegravir or raltegravir and are appropriate whether the exposure was occupational or nonoccupational.</div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">== Prophylaxie pré-expositionnelle (PrEP) ==</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* The combination of tenofovir disoproxil fumarate (or tenofovir alafenamide, except in women engaging in receptive vaginal intercourse) plus emtricitabine taken once daily is more than 90% effective, if taken consistently, in preventing HIV acquisition.</ins></div></td></tr> <tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">* &lt;u&gt;Indications:&lt;/u&gt; Data support the use of pre-exposure prophylaxis (PrEP) in specific populations with ongoing high risk for infection, such as sexual partners of infected persons, men who have sex with men, and injection drug users. PrEP is recommended for persons in such groups who can adhere to the daily regimen.</ins></div></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>== Références ==</div></td></tr> </table>

Julien https://médecine.top/index.php?title=Infection_%C3%A0_HIV&diff=2708&oldid=prev 2020-06-18T14:36:01Z

<p>Page créée avec « == Prophylaxie post-expositionnelle (PEP) == * Preferred HIV postexposure prophylaxis regimens include tenofovir disoproxil fumarate, emtricitabine, and either dolutegrav... »</p> <p><b>Nouvelle page</b></p><div><br /> == Prophylaxie post-expositionnelle (PEP) ==<br /> * Preferred HIV postexposure prophylaxis regimens include tenofovir disoproxil fumarate, emtricitabine, and either dolutegravir or raltegravir and are appropriate whether the exposure was occupational or nonoccupational.<br /> <br /> == Références ==<br /> MKSAP 2018<br /> <br /> [[Category:Infectiologie]]</div>

Julien